Ascendis Pharma (NasdaqGS:ASND) FY Conference Transcript

Ascendis Pharma FY Conference Summary Company Overview - Company: Ascendis Pharma (NasdaqGS:ASND) - Event: 46th Annual TD Cowen Healthcare Conference - Date: March 02, 2026 Key Points Product Launch and Approval - Ascendis Pharma received approval for UVEVELL, a new treatment for hypoparathyroidism, with a clean label and minimal adverse events [3][4] - The drug is designed for weekly administration and can be stored at room temperature for up to 6 months, differentiating it from competitors like VOXZOGO [3] - The launch is expected in early Q2 2026, pending final packaging information from the FDA [4] Market Potential - There are approximately 2,600 patients diagnosed with hypoparathyroidism in the U.S., with only 30% currently receiving treatment [4][8] - Ascendis aims to target both existing patients on other therapies and new patients who are currently untreated [9][10] - The company believes that a significant portion of patients will switch to YORVIPATH due to its benefits over existing treatments [9][10] Competitive Landscape - VOXZOGO has a known risk of blood pressure changes requiring hydration, while YORVIPATH does not have such stringent requirements, which may enhance its appeal [12][13] - Ascendis plans to price YORVIPATH at a premium, reflecting its superior benefits, but will also consider contracting with payers to maximize access [19][20] Patient Engagement and Market Penetration - Ascendis emphasizes a patient-focused approach, engaging with patient groups to understand their needs and improve treatment uptake [29][30] - The company believes that addressing comorbidities will drive treatment rates, with expectations that 70-80% of patients will eventually seek treatment [33][34] Future Developments - Ascendis is also exploring a once-weekly version of YORVIPATH, which may require a different regulatory pathway for approval [44][45] - The company is focused on ensuring optimal patient journeys and minimizing dropouts during the treatment initiation phase [42][43] Financial Considerations - The company anticipates that the pricing strategy and patient support systems will help maintain demand and manage gross-to-net revenue dynamics [35][37] Conclusion - Ascendis Pharma is positioned to capitalize on the unmet needs in the hypoparathyroidism market with its innovative treatment YORVIPATH, leveraging its patient-centric approach and strategic pricing to enhance market penetration and patient outcomes [20][29][33]